Ribociclib (Riboxiclib) for Breast Cancer: A Complete Patient Guide to Medication

Ribociclib (Ribociclib), known to most patients under the trade name Kisqali, is a therapeutic drug for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer. It inhibits the growth of cancer cells by inhibiting specific cell cycle protein kinases. The following is a detailed introduction and usage guidelines for Ribociclib.

1. Overview of Drugs

Ribociclib mainly acts on cyclin-dependent kinases4/6 (CDK4/6). Inhibition of these kinases can effectively block the proliferation of cancer cells. It is often used with an aromatase inhibitor (such as letrozole) as initial endocrine therapy in women with breast cancer.

2. How it works

Ribociclib prevents cancer cells fromG1 phase enters the S phase, thus cutting off its ability to DNA replicate and divide. This mechanism prevents cancer cells from continuing to grow and effectively controls the spread of tumors.

3. Drug Metabolism and Kinetics

After oral administration of ribociclib is rapidly absorbed, typically reaching peak blood concentrations within 1 to 5 hours. The drug is widely distributed in the body and approximately 70% is bound to plasma proteins. It is mainly metabolized by the liver's CYP3A4 enzyme, and ultimately most of it is excreted through feces, and a small part is excreted through urine. The half-life of the drug in the body is approximately 32 hours.

4. Medication guidance

Recommended dose: When starting treatment, the usual recommended dose is 600mg once daily (equivalent to 3 tablets200mg tablets), take it continuously for 21 days and then stop taking it for 7 days to complete a 28 day treatment cycle.

Co-administration: When used concomitantly with an aromatase inhibitor (such as letrozole), letrozole should be taken once daily at a recommended dose of 2.5 mg.

Dose adjustment: If serious adverse reactions occur, such as a significant decrease in neutrophils, the dose should be adjusted or the medication should be suspended according to the doctor's recommendations. After the side effects are relieved, the dose can be gradually returned to the recommended level, but should not exceed the standard.

5. Possible adverse reactions

Common reactions include decreased neutrophil counts (required to be monitored with regular blood tests), increased liver enzyme levels (required to undergo regular liver function tests), nausea and vomiting (relieved by dietary modification and medication), fatigue, and hair loss (these reactions are usually temporary).

Severe reactions may include QT prolongation (requires regular electrocardiograms to prevent arrhythmias) and increased risk of infection due to neutropenia (requires close monitoring and prompt management of infection symptoms).

6. Precautions for use

1.Before starting treatment, patients should undergo a comprehensive health examination, including blood, liver function and electrocardiogram tests.

2.The above examinations should be carried out regularly during treatment to detect and deal with any adverse reactions in a timely manner.

3.Patients should avoid concurrent use of strongCYP3A4inhibitors or inducers and should inform their physician of all medications and supplements they are taking to avoid adverse drug interactions. Additionally, grapefruit juice may increase concentrations of ribociclib in the blood and should be avoided.

7. Taboo

1.It should not be used by patients who are allergic to ribociclib or any of its ingredients.

2.It is contraindicated in pregnant and lactating women becauseribociclib (ribociclib) may cause harm to the fetus or infant.

3.Patients with severe hepatic insufficiency should also not use it, because Ribociclib (ribociclib) is mainly metabolized by the liver, and hepatic insufficiency may cause the drug to accumulate in the body and increase the risk of toxicity.

Ribociclib (Riboxiclib) is a leading-edge CDK4/6 inhibitor that significantly improves treatment options for HR+/HER2- breast cancer patients. By following scientific medication guidance and comprehensive management measures, patients can maximize the benefits from Ribociclib treatment, significantly extend progression-free survival and improve overall quality of life.